

# Mauro Cataldi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1334945/publications.pdf>

Version: 2024-02-01

86  
papers

2,746  
citations

186265

28  
h-index

197818

49  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4424  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flavonoids and Î³-polyunsaturated fatty acid supplementation in renal transplant recipients: new arguments from COVID-19. <i>Journal of Nephrology</i> , 2022, 35, 95-97.	2.0	0
2	From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome). <i>Current Obesity Reports</i> , 2022, , .	8.4	10
3	New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. <i>Advances in Therapy</i> , 2021, 38, 2094-2113.	2.9	5
4	Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	2
5	The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19. <i>Frontiers in Physiology</i> , 2021, 12, 653985.	2.8	5
6	Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?. <i>Viruses</i> , 2021, 13, 1285.	3.3	9
7	Facilitators and barriers for the implementation of a telemedicine program in nutrition during the COVID-19 pandemic. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2987-2988.	2.6	1
8	Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12947.	4.1	4
9	Cardiovascular effects of antiobesity drugs: are the new medicines all the same?. <i>International Journal of Obesity Supplements</i> , 2020, 10, 14-26.	12.6	5
10	Identification of sarcopenia and dynapenia in CKD predialysis patients with EGWSOP2 criteria: An observational, cross-sectional study. <i>Nutrition</i> , 2020, 78, 110815.	2.4	13
11	Neurobiology of coronaviruses: Potential relevance for COVID-19. <i>Neurobiology of Disease</i> , 2020, 143, 105007.	4.4	42
12	Assessment of Body Composition in Health and Disease Using Bioelectrical Impedance Analysis (BIA) and Dual Energy X-Ray Absorptiometry (DXA): A Critical Overview. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.8	168
13	Cardiac safety of second-generation H <sub>1</sub> -antihistamines when up-dosed in chronic spontaneous urticaria. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1615-1623.	2.9	33
14	Prevalence of obesity and obesity-associated muscle wasting in patients on peritoneal dialysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1390-1399.	2.6	11
15	A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy. <i>Epilepsia Open</i> , 2019, 4, 464-475.	2.4	29
16	Amyloid Î²-Induced Upregulation of Nav1.6 Underlies Neuronal Hyperactivity in Tg2576 Alzheimer's Disease Mouse Model. <i>Scientific Reports</i> , 2019, 9, 13592.	3.3	49
17	Gender-related issues in the pharmacology of new anti-obesity drugs. <i>Obesity Reviews</i> , 2019, 20, 375-384.	6.5	28
18	The impact of a nutritional intervention based on egg white for phosphorus control in hemodialysis patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 45-50.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 275-280.	1.2	1
20	Single-unit Activity in the in vitro Entorhinal Cortex During Carbachol-induced Field Oscillations. Neuroscience, 2018, 379, 1-12.	2.3	5
21	Predictors of fat-free mass loss 1 year after laparoscopic sleeve gastrectomy. Journal of Endocrinological Investigation, 2018, 41, 1307-1315.	3.3	21
22	The evolving concept of the intrinsic hippocampal theta gamma oscillator. Frontiers in Bioscience - Scholar, 2018, 10, 143-165.	2.1	8
23	Preclinical characterization of eleven new Cys-PEGylated hGH mutants. European Journal of Molecular and Clinical Medicine, 2017, 2, 147.	0.1	0
24	VEGF mimic peptides: Potential applications in central nervous system therapeutics. European Journal of Molecular and Clinical Medicine, 2017, 3, 233.	0.1	3
25	Carbachol-induced network oscillations in an in vitro limbic system brain slice. Neuroscience, 2017, 348, 153-164.	2.3	8
26	Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases. EMBO Molecular Medicine, 2017, 9, 112-132.	6.9	65
27	Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. Journal of the American College of Nutrition, 2017, 36, 586-591.	1.8	21
28	Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. International Journal of Molecular Sciences, 2017, 18, 1249.	4.1	181
29	Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study. In Vivo, 2017, 31, 709-712.	1.3	4
30	Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy. BMC Pharmacology & Toxicology, 2016, 17, 9.	2.4	7
31	Short-Term Changes in Body Composition and Response to Micronutrient Supplementation After Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2015, 25, 2344-2351.	2.1	50
32	Neuroprotective Effect of VEGF-Mimetic Peptide QK in Experimental Brain Ischemia Induced in Rat by Middle Cerebral Artery Occlusion. ACS Chemical Neuroscience, 2015, 6, 1517-1525.	3.5	24
33	Histamine Receptors and Antihistamines: From Discovery to Clinical Applications. Chemical Immunology and Allergy, 2014, 100, 214-226.	1.7	42
34	Biofilm-dependent airway infections: A role for ambroxol?. Pulmonary Pharmacology and Therapeutics, 2014, 28, 98-108.	2.6	26
35	Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clinical Nutrition, 2014, 33, 399-405.	5.0	71
36	Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1043-1049.	2.6	125

#	ARTICLE	IF	CITATIONS
37	Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients?. PLoS ONE, 2014, 9, e95811.	2.5	30
38	Resting state networks in temporal lobe epilepsy. Epilepsia, 2013, 54, 2048-2059.	5.1	142
39	Transcriptional Regulation of ncx1 Gene in the Brain. Advances in Experimental Medicine and Biology, 2013, 961, 137-145.	1.6	14
40	Genetically Modified Mice as a Strategy to Unravel the Role Played by the Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger in Brain Ischemia and in Spatial Learning and Memory Deficits. Advances in Experimental Medicine and Biology, 2013, 961, 213-222.	1.6	19
41	Dietary Intake as a Link between Obesity, Systemic Inflammation, and the Assumption of Multiple Cardiovascular and Antidiabetic Drugs in Renal Transplant Recipients. BioMed Research International, 2013, 2013, 1-8.	1.9	15
42	Effects of a Diet Rich in N-3 Polyunsaturated Fatty Acids on Systemic Inflammation in Renal Transplant Recipients. Journal of the American College of Nutrition, 2013, 32, 375-383.	1.8	12
43	Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. PLoS ONE, 2013, 8, e73558.	2.5	27
44	The Antiepileptic Drug Levetiracetam Suppresses Non-Convulsive Seizure Activity and Reduces Ischemic Brain Damage in Rats Subjected to Permanent Middle Cerebral Artery Occlusion. PLoS ONE, 2013, 8, e80852.	2.5	29
45	The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases. Current Neuropharmacology, 2013, 11, 276-297.	2.9	32
46	ERK1/2, p38, and JNK regulate the expression and the activity of the three isoforms of the Na <sup>+</sup> /Ca <sup>2+</sup> exchanger, NCX1, NCX2, and NCX3, in neuronal PC12 cells. Journal of Neurochemistry, 2012, 122, 911-922.	3.9	27
47	1,4-dihydropyridines: the multiple personalities of a blockbuster drug family. Translational Medicine @ UniSa, 2012, 4, 12-26.	0.5	8
48	Preliminary Finding on a New Calcium Channel Entry Blocker Chemotype: 5,6-Diamino-4-hydroxy-2-mercaptopyrimidine Derivatives. Journal of Medicinal Chemistry, 2011, 54, 5597-5601.	6.4	3
49	Involvement of inward rectifier and M-type currents in carbachol-induced epileptiform synchronization. Neuropharmacology, 2011, 60, 653-661.	4.1	12
50	Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to <sup>11</sup> 9-THC. Pharmacological Research, 2010, 61, 334-341.	7.1	35
51	T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. Neuropharmacology, 2009, 56, 637-646.	4.1	29
52	An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Letters, 2008, 582, 1141-1146.	2.8	36
53	Glutamate-Independent Calcium Toxicity. Stroke, 2007, 38, 661-664.	2.0	27
54	Zn <sup>2+</sup> Slows Down CaV3.3 Gating Kinetics: Implications for Thalamocortical Activity. Journal of Neurophysiology, 2007, 98, 2274-2284.	1.8	19

#	ARTICLE	IF	CITATIONS
55	ncx1, ncx2, and ncx3 Gene Product Expression and Function in Neuronal Anoxia and Brain Ischemia. <i>Annals of the New York Academy of Sciences</i> , 2007, 1099, 413-426.	3.8	41
56	Nitric oxide induces $[Ca^{2+}]_i$ oscillations in pituitary GH3 cells: involvement of IDR and ERG K <sup>+</sup> currents. <i>American Journal of Physiology - Cell Physiology</i> , 2006, 290, C233-C243.	4.6	24
57	The Antiepileptic Drug Levetiracetam Decreases the Inositol 1,4,5-Trisphosphate-Dependent $[Ca^{2+}]_i$ Increase Induced by ATP and Bradykinin in PC12 Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 720-730.	2.5	42
58	Imatinib-Mesylate Blocks Recombinant T-Type Calcium Channels Expressed in Human Embryonic Kidney-293 Cells by a Protein Tyrosine Kinase-Independent Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 208-215.	2.5	26
59	First- and second-generation H1 antihistamines: from the molecular basis of their interaction with HERG K <sup>+</sup> channels to physiological and pathophysiological implication. <i>Clinical and Experimental Allergy Reviews</i> , 2004, 4, 183-190.	0.3	2
60	Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions. <i>Toxicology Letters</i> , 2003, 139, 125-133.	0.8	236
61	Differences in Apparent Pore Sizes of Low and High Voltage-activated Ca <sup>2+</sup> Channels. <i>Journal of Biological Chemistry</i> , 2002, 277, 45969-45976.	3.4	41
62	Modulation of ion channels by reactive oxygen and nitrogen species: a pathophysiological role in brain aging?. <i>Neurobiology of Aging</i> , 2002, 23, 819-834.	3.1	111
63	Pharmacological Blockade of ERG K <sup>+</sup> Channels and Ca <sup>2+</sup> Influx through Store-Operated Channels Exerts Opposite Effects on Intracellular Ca <sup>2+</sup> Oscillations in Pituitary GH <sub>3</sub> Cells. <i>Molecular Pharmacology</i> , 2000, 58, 1115-1128.	2.3	32
64	Effects of manidipine and nitrendipine enantiomers on the plateau phase of K <sup>+</sup> -induced intracellular Ca <sup>2+</sup> increase in GH3 cells. <i>European Journal of Pharmacology</i> , 1999, 376, 169-178.	3.5	12
65	Involvement of phosphodiesterase-cGMP-PKG pathway in intracellular Ca <sup>2+</sup> oscillations in pituitary GH3 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1999, 1449, 186-193.	4.1	18
66	In the neuronal cell line SH-SY5Y, oxidative stress-induced free radical overproduction causes cell death without any participation of intracellular Ca <sup>2+</sup> increase. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1999, 1452, 151-160.	4.1	61
67	Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. <i>Obstetrical and Gynecological Survey</i> , 1998, 53, 287-289.	0.4	0
68	Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3574-3579.	3.6	146
69	Another view of GH neuroregulation: lessons from the sheep. <i>European Journal of Endocrinology</i> , 1997, 136, 553-565.	3.7	33
70	Protein-tyrosine Kinases Activate while Protein-tyrosine Phosphatases Inhibit L-type Calcium Channel Activity in Pituitary GH3 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 9441-9446.	3.4	82
71	Effect of actively immunizing sheep against growth hormone-releasing hormone or somatostatin on spontaneous pulsatile and neostigmine-induced growth hormone secretion. <i>Journal of Endocrinology</i> , 1995, 144, 83-90.	2.6	29
72	Role of the Na <sup>+</sup> -Ca <sup>2+</sup> and Na <sup>+</sup> -H <sup>+</sup> antiporters in prolactin release from anterior pituitary cells in primary culture. <i>European Journal of Pharmacology</i> , 1995, 294, 11-15.	3.5	10

#	ARTICLE	IF	CITATIONS
73	Effect of tianeptine on the hypothalamic somatotropic axis in the conscious sheep. <i>European Journal of Pharmacology</i> , 1994, 253, 149-153.	3.5	7
74	Acute stress stimulates secretion of GHRH and somatostatin into hypophysial portal blood of conscious sheep. <i>Neuroscience Letters</i> , 1994, 178, 103-106.	2.1	22
75	Relationship between hypophyseal portal GHRH and somatostatin and peripheral GH levels in the conscious sheep. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 717-722.	3.3	32
76	Role of growth hormone (GH)-releasing hormone and somatostatin in the mediation of clonidine-induced GH release in sheep. <i>Endocrinology</i> , 1994, 134, 562-567.	2.8	8
77	Alpha-Melanocyte-Stimulating Hormone Is Present in the Inferior Petrosal Sinuses in Patients with Cushing's Disease. <i>Neuroendocrinology</i> , 1993, 58, 227-233.	2.5	5
78	Neostigmine stimulates growth hormone-releasing hormone release into hypophysial portal blood of conscious sheep. <i>Endocrinology</i> , 1993, 132, 1247-1251.	2.8	13
79	Effects of metyrapone infusion on corticotropin-releasing factor and arginine vasopressin secretion into the hypophysial portal blood of conscious, unrestrained rams. <i>European Journal of Endocrinology</i> , 1992, 127, 435-440.	3.7	21
80	Evaluation of GH Paradoxical Responses to TRH and LHRH in Acromegalic Patients during Long-Term Treatment with Octreotide. <i>Hormone Research</i> , 1992, 37, 18-22.	1.8	7
81	Serum Thyrotropin Response to Combined Arginine and Thyrotropin-Releasing Hormone Administration Provides Evidence for an Altered Somatostatinergetic Tone in Acromegaly. <i>Hormone Research</i> , 1992, 37, 7-13.	1.8	10
82	Further Evaluation of IGF-I Responsiveness to ACTH in Children Affected with IGHD. <i>Hormone Research</i> , 1992, 38, 150-153.	1.8	2
83	Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long acting somatostatin analog, in rams. <i>Life Sciences</i> , 1992, 51, 831-838.	4.3	38
84	Effect of chronic active immunization anti-corticotropin-releasing factor on the pituitary-adrenal function in the sheep. <i>Endocrinology</i> , 1992, 130, 2291-2298.	2.8	17
85	Effect of chronic active immunization with antiarginine vasopressin on pituitary-adrenal function in sheep. <i>Endocrinology</i> , 1992, 130, 3007-3014.	2.8	9
86	Effect of a short-term treatment with recombinant growth hormone (GH) on adrenal responsiveness to corticotrophin stimulation in children affected by isolated GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 1210-1214.	3.6	8